introduction Lung cancer is the leading cause of cancer, and cancer-related death worldwide [1, 2] . Although early diagnosis is uncommon and the vast majority of patients are diagnosed at a non-curable stage [3] , patients with localized cancer can be managed curatively with complete surgical resection with or without postoperative treatment. In a series of recent trials [4] [5] [6] , the survival advantage of platinum-based adjuvant chemotherapy has been proven, and is accepted as a standard treatment in stage II to IIIA non-small-cell lung cancer (NSCLC).
As with other malignancies, the incidence of lung cancer increases with age. More than half of all patients with the diagnosis are over the age of 65, and ∼30% are 70 years and older [7, 8] . Given the increasing comorbid conditions and progressive reduction of organ functions [9, 10] , it is presumed that the elderly are less likely to tolerate chemotherapy. As a result, many of the trials that have established the benefit of adjuvant chemotherapy in early-stage NSCLC had eligibility criteria with an upper limit of age, which restricted the participation of elderly patients. Consequently, prospective data on adjuvant chemotherapy in elderly patients are very limited, and the treatment decision in these patients remains a great challenge.
Recently, there have been retrospective analyses regarding the association of age with the clinical outcome of NSCLC patients treated with adjuvant chemotherapy [11] [12] [13] [14] [15] [16] ; in these reports, survival advantage was similarly observed in elderly patients with an acceptable toxicity profile. Also, there was a more extensive literature on the treatment outcome of the elderly with metastatic NSCLC which shows that chemotherapy is better than no chemotherapy in aspects of survival [17, 18] , and that a platinum doublet is better than one drug even in the elderly [19] . Taken together, these served as scientific evidence that elderly NSCLC patients should not be excluded from treatment based on age.
In addition to survival advantage for elderly patients, general well-being of individuals, usually referred to as 'quality of life (QOL)', is another significant factor and outcome [17, 18, 20] which ought to be considered before initiating treatment. Although expectations for treatment in elderly may be different according to individuals' outlook on life; for example, some may value QOL over life expectancy, whereas some prefer life expectancy to QOL, there has been a scarcity of evidence for QOL with adjuvant chemotherapy in this population. Therefore, clinical studies specifically designed for the assessment of QOL in elderly are urgently needed for making optimal treatment decisions.
In this study, we prospectively evaluated and compared the QOL of patients aged ≥65 with patients <65 who were treated with postoperative chemotherapy for NSCLC.
patients and methods inclusion criteria
Between October 2008 and October 2011, patients who fulfilled the following criteria and were planned to receive postoperative chemotherapy were enrolled for this analysis: histologically confirmed, completely resected stage Ib, II or IIIa NSCLC; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; no prior treatment with radiation, chemotherapeutic agent or biologic response modifier; adequate bone marrow, renal and hepatic function; and written informed consent. Patients presenting with any of the following were not eligible in this study: concomitant acute or chronic medical illness conditions (myocardial infarction, severe/unstable angina, congestive heart failure and cerebrovascular accident within 6 months before starting postoperative chemotherapy, ongoing cardiac dysarhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, uncontrolled hypertension and uncontrolled diabetes mellitus); prior malignancy other than current NSCLC within the last 5 years (except in cases of non-melanoma skin cancer or localized cervical cancer, or localized and presumed cured prostate cancer). This study was approved by the institutional review boards of Samsung Medical Center. 
data collection and HRQOL measures
For the assessment of health-related quality of life (HRQOL), the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) [21, 22] and lung-specific questionnaire (LC13) [23] were used. Questionnaires were self-completed by patients before receiving the first dose of treatment at each cycle, and at 1 month after completion of the last fourth cycle, totaling up to five times of QOL measurements per patient. The QLQ-C30 measure comprises of nine multiple-item scales and six single items. Multiple-item scales of QLQ-C30 consisted of six functional scales ( physical, role, emotional, cognitive, social and global QOL) and three symptom scales (fatigue, nausea and vomiting, pain). Six single-item scales of QLQ-C30 involve dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. The QLQ-LC13 includes 13 items assessing lung cancerrelated symptoms (cough, hemoptysis, dyspnea and site-specific pain), treatment-related adverse effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and the use of pain medications. All scales of QLQ-LC13 are single-item scales except for the dyspnea scale. The scale was calculated using those items for which the values existed and all of the scales ranged in score from 0 to 100. Regarding multi-item scales, they were presented with the mean score of the relevant items, and transformed to a score ranging from 0 to 100. For the overall QOL and functioning scales, a higher score is correlated with better HROQL, whereas a higher score represents worse HRQOL for symptom scales.
statistical consideration
This is a pilot study designed to enroll 140 patients who were treated with a postoperative chemotherapy for NSCLC. The primary objective was to assess the HRQOL of elderly patients (age ≥65 years) prospectively, during and after receiving postoperative chemotherapy for NSCLC. The secondary objectives included the comparison of the HRQOL, hematologic toxic effects, chemotherapy delivery and treatment outcomes, including overall survival (OS) and relapse-free survival (RFS) between two age groups (≥65 . The time trend of HROQL was estimated by a linear model using the generalized estimating method (GEE) based on the working independence structure [24, 25] . Differences in clinical characteristics, hematologic toxic effects and chemotherapy delivery according to age groups were examined using the X 2 -test (or Fisher's exact test) for categorical variables, and the Mann-Whitney test for continuous nonparametric variables. OS and RFS distributions were estimated by the Kaplan-Meier method and compared using the log-rank test. P values <0.05 were considered statistically significant, and all P values reported in this paper are two-sided.
results baseline characteristics
A total of 139 patients were consecutively entered into the study. The clinicopathologic characteristics of all patients are listed in Table 1 , and were compared between patient groups with different ages (young: age <65, elderly: age ≥65). Sixty-six Among the patients with smoking history only. patients were ≥65 years of age and 73 patients were <65 years. The median age of all patients was 64 years (range 32-82). The median age was 56 years in the young patient group, and 69 years in the elderly group. There were more men (82.0%) than women (18.0%), and the difference was more prominent in the elderly patient group (P = 0.009). One hundred and eight patients (77.7%) had smoking history. Compared with the young, the proportion of smokers was significantly higher in the elderly, and older patients showed higher proportion of heavy smokers defined by ≥30 pack-years of smoking history (56.0% in the young and 77.6% in the elderly, P = 0.017). Comorbid conditions were classified as the presence or absence of any of the following conditions: diabetes mellitus, heart disease, cerebrovascular disease, venous thrombosis, pulmonary disease (e.g. chronic obstructive lung disease, interstitial lung disease) and liver disease (e.g. chronic hepatitis B infection and chronic hepatitis C infection), which do not meet the exclusion criteria. A total of 34 comorbid conditions were identified in 29 patients, and the elderly were significantly more likely to have comorbidity (28.8%) compared with the young (13.7%) (P = 0.029). Adenocarcinoma comprised of the largest proportion of histologic subtypes in all patients (49.6%), but the distribution of histologic subtypes between the two age groups was significantly different: adenocarcinoma was most common in the young (61.6%), whereas squamous cell carcinoma was most common in the elderly (56.1%) (P = 0.007). Among the chemotherapeutic regimens, adjuvant therapy using vinorelbine plus cisplatin was more frequently used in the young (60.3%). In contrast, the elderly were more frequently treated with the paclitaxel plus carboplatin regimen completion of HRQOL questionnaire Table 2 lists the number of patients who completed QOL questionnaire data according to the designated time point. One hundred and twenty-seven patients (91.4%) completed the questionnaire, and the proportion of patients was similar between the two age groups, 91.8% in the young and 90.9% in the elderly. Although the response to the survey attenuated over time, >90% of questionnaires were completed in both the groups.
QOL of elderly patients during and after receiving postoperative chemotherapy compared with baseline QOL
Each of QLQ-C30 and QLQ-LC13 scales was regressed on the age group (=0 for the elderly and =1 for the young groups), time and their interaction using a linear model. Table 3 shows the results of the analysis of QLQ-C30 using GEE statistics. In the linear model, a time trend for the elderly group can be tested by the P value of the 'time' parameter. At α = 5% level, none of the functioning scales showed any changes in QOL over time. Fatigue, nausea/ vomiting and pain, designated as symptom scales/items, did not have a time trend in the elderly patient group. Of the six single-item scales, there were significant differences in improvement or worsening of sleep disturbance (P = 0.0066), appetite loss (P = 0.0186) and constipation (0.0004) over time. Figure 1A shows the time trend of these symptom scores in elderly patients (continuous line), all of which were worsened after the first chemotherapy cycle. Sleep disturbance and appetite loss were gradually improved during the remaining chemo cycles, but constipation was more aggravated with treatment. QLQ-LC13 analysis results are also given in Table 3 . Among lung cancer-related symptoms, cough showed a time difference since treatment initiation (P = 0.0054). As shown in Figure 1B , cough was more aggravated after the first cycle, but improved over time. During treatment with cytotoxic chemotherapy, sore mouth (P = 0.0032), peripheral neuropathy (P < 0.001) and alopecia (P < 0.001) were main adverse effects experienced and changed over time ( Figure 1B) for elderly patients. Contrary to pain in other sites, pain in the arm or shoulder was significantly changed with time (P = 0.0104), especially after two cycles of chemotherapy ( Figure 1B) .
comparison of the HRQOL by age groups Figure 1A and B depicts an overview of HRQOL comparison between the young (dotted line) and the elderly (continuous line) groups during four cycles of postoperative chemotherapy.
In the linear regression model fitted using the GEE method, the parameter 'age_gr' in Table 3 is to test whether two age groups have a different QOL level before treatment initiation and the interaction term (age_gr*time) is to compare the difference in time trend between the two groups. From Table 3 , we observed that no baseline QOL levels were significantly different between the two age groups. Furthermore, no functioning scales had any significant difference in time trend between the two age groups. Among the symptom scales, constipation attained a significance in the time trend between the two groups (P = 0.0207), where the symptom worsened progressively over time in both the groups with more pronounced change in the elderly.
hematologic toxicities and chemotherapy delivery by age groups Table 4 shows hematologic toxic effects by age group. Among toxic effects of all grades, none but anemia was significantly different between the two age groups; anemia was more frequently observed in elderly patients (39.7% versus 60.6%, P = 0.014). Neutropenia was most common, accounting for 80.8% and 66.7% in the young and the elderly. The frequency of grade 3 or higher toxic effects did not significantly differ between the age groups. Of total, 130 patients (93.5%) completed planned chemotherapy and 9 patients (6.5%) did not as shown in Table 1 . Sixty nine of younger patients (94.5%) and 61 of older patients (92.4%) completed all courses of chemotherapy, which was not significantly different between the age groups (P = 0.736). During chemotherapy, 81 patients (58.3%) experienced dose modification, and the proportion of patients with dose reduction were 57.5% and 59.1% in the young and the elderly, respectively (P = 0.853). Dose intensity was calculated (Table 5) , and all patients who received at least one dose of chemotherapy were included in this analysis. The mean dose intensities (MDIs) for vinorelbine and cisplatin were higher in the elderly group, whereas the MDIs for paclitaxel and carboplatin were higher in the young group, although none of these were significantly different between the two age groups.
OS and RFS
With the median follow-up of 31.9 months (range 7.6-45.4), the 3-year OS and RFS were 91.8% and 62.2% in the elderly, and 82.6% and 69.5% in the younger, respectively. The differences in OS and RFS were not statistically significant between the two age groups (P = 0.4274 for OS and P = 0.4512 for RFS).
discussion
In clinical practice, it can be challenging to make appropriate treatment decisions for the elderly patients requiring adjuvant chemotherapy based on their disease stage. Elderly patients tend to have more comorbidities with a decline in physiologic reserves, which may substantially limit life expectancy. In addition, a number of age-related changes may induce pharmacodynamic changes, which potentially deteriorate organ function and decrease drug tolerability. However, aging being a heterogeneous and varying process is not always correlated with adverse physiological functions [26] . Because each patient's senescent pattern is unique, generalization based on age alone should be refrained. Age should be considered but according to individual's clinical characteristics. In view of this complex aging process that varies from individual to individual, the decision to administer chemotherapy to elderly becomes more perplex and necessitates careful consideration. Assessing the risks and benefits of postoperative chemotherapy for the elderly, there could be different views. Objective outcomes such as survival benefit, toxic effects and duration of hospitalization can be reasonable parameters for assessing the risk-benefit ratio. In fact, many recently published studies have focused on these end points [11-14, 16, 27] , and reached a general consensus that survival benefit of adjuvant chemotherapy in elderly patients was comparable with that of younger patients with acceptable toxic effects. However, these objective outcomes may have limitations in Depending on patients' perspectives on therapeutic objectives, patients may choose treatment that yields improvement in quality of life instead of life expectancy. As a result, comprehensive assessment that can reflect patients' subjective well-being beyond objective measurement is indispensable not only in providing better information to patients of this population and to physicians, but also in making informed decisions for optimal treatments. In this study, we identified QOL change in elderly patients with adjuvant chemotherapy after curative resection for NSCLC. The measurement of QOL incorporates a broad spectrum of daily living activities including physical function, role, emotion, cognition, social activity, financial problem, disease-related symptoms and treatment-related toxic effects. We hypothesized that the overall QOL would decrease with postoperative chemotherapy in elderly patients compared with younger patients, and therefore, the difference in QOL would become more prominent between the two age groups. As shown in this study, however, the overall QOL in elderly patients did not significantly deteriorate with adjuvant chemotherapy. Moreover, the time trend of QOL in elderly patients was similar to that of younger patients. Constipation was the only symptom that the older patients had experienced more discomfort than their younger counterparts, which is probably due in part to the usage of opioid for pain control. Sleep disturbance, appetite loss and coughing were rather improved with time. Although the elderly suffered from increased treatment-related adverse events involving sore mouth, peripheral neuropathy and alopecia compared with the baseline, similar time trends were also observed in the younger group. Based on these results, the presumption that the elderly are more susceptible to toxic effects related to adjuvant chemotherapy may not always hold true, at least when patients are selected appropriately.
Despite the prospective nature of this study, there are several limitations in the current study. A cut-off age of 65 was arbitrarily selected for the analysis, and the median age of the elderly group was not over 70 years. Although the age of 65 is usually considered a cut-off point to identify an elderly population within epidemiologic literature [28] , the age of 70 has been frequently used as a lower limit for patient selection in clinical trials [26, 29] and likewise, a cut-off age of ≥70 was used to represent the elderly in some studies [14, 16] . We have also restricted the patients' enrollment to ECOG 0-1 and adequate organ function, which may not represent elderly patients in clinical practice. Furthermore, if there were QOL measurements from the patients who refused chemotherapy and were observed only, then a direct comparison of patients' QOL based on whether they received chemotherapy or not would have been available. However, this was not the case in this study. In addition, weakness of statistical power might be attributed to small number of patients enrolled. Nevertheless, this study certainly has its own strengths. To the best of our knowledge, this is the first prospective study specifically designed for elderly patients treated with adjuvant chemotherapy in NSCLC; almost all information of the elderly reported before has been drawn from a subgroup analysis [11] or a meta-analysis [12, 14, 30] . And, selection of 'QOL' as a primary end point for assessing the effect of adjuvant chemotherapy has not been extensively studied before.
In conclusion, postoperative chemotherapy did not substantially reduce HRQOL in elderly NSCLC patients, and the HRQOL during and after adjuvant chemotherapy did not significantly differ by age (<65 years versus ≥65 years). The results of this prospective study provide evidence that age alone is not a determinant factor for making optimal treatment decisions in elderly and support the use of postoperative chemotherapy in those elderly individuals deemed as appropriate. More studies are warranted to confirm our findings.
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